Provenienza dei contatti di primo grado di Lukas Rindlisbacher
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals.
13
| Private Company | Investment Managers | 13 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Lukas Rindlisbacher tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
TRACON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
PELOTON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
TURG POIN | Pharmaceuticals: Major | Director/Board Member | |
PineBridge Global Funds - Asia (ex-Japan) Small Cap Equity Fd.
PineBridge Global Funds - Asia (ex-Japan) Small Cap Equity Fd. Investment Trusts/Mutual FundsMiscellaneous PineBridge Global Funds-Asia ex Japan Small Cap Equity Fund provides investment services. It invests in companies in the ''Asian Region'' countries including Hong Kong, India, Indonesia, Malaysia, Pakistan, China, Philippines, Singapore, Sri Lanka, Taiwan, and Thailand. The company was incorporated on 15th December, 1993 and is headquartered in Dublin, Ireland. | Investment Trusts/Mutual Funds | Director/Board Member | |
PineBridge Global Funds - Greater China Equity Fund
PineBridge Global Funds - Greater China Equity Fund Investment Trusts/Mutual FundsMiscellaneous PineBridge Greater China Equity Fund provided investment services. It was an open-ended investment company with variable capital under the European Communities Regulations, 2003. It was founded in October, 2002 and was headquartered in Dublin, Ireland. | Investment Trusts/Mutual Funds | Director/Board Member | |
Karolinska Institutet | College/University | Doctorate Degree | |
University of California, Los Angeles | College/University | Doctorate Degree | |
Technische Universität Darmstadt | College/University | Undergraduate Degree | |
University of Zurich | College/University | Doctorate Degree | |
Swiss Federal Institute of Technology | College/University | Chief Administrative Officer | |
University of Anglia Ruskin | College/University | Undergraduate Degree | |
Amgen Ltd.
Amgen Ltd. Miscellaneous Commercial ServicesCommercial Services Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Ecole Supérieure de Technologie des Biomolécules de Bordeaux | College/University | Graduate Degree | |
BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
ImaginAb, Inc.
ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
SYROS PHARMACEUTICALS, INC. | Biotechnology | Founder | |
Circle Pharma, Inc.
Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
ARVINAS, INC. | Biotechnology | Director/Board Member | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
IDEAYA BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
RELAY THERAPEUTICS, INC. | Biotechnology | Founder | |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Rising Tide Foundation | Investment Trusts/Mutual Funds | Director/Board Member | |
Hexagon Bio, Inc.
Hexagon Bio, Inc. BiotechnologyHealth Technology Hexagon Bio, Inc. operates as a data-driven biotechnology company. It engages in mining of fungal genome data for drugs. The company was founded by Maureen E. Hillenmeyer, Brian T. Naughton, Colin James Bell Harvey and Yi Tang and is headquartered in Menlo Park, CA. | Biotechnology | Director/Board Member | |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | Miscellaneous Commercial Services | Director/Board Member | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
KRONOS BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
TYRA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
BOUNDLESS BIO, INC. | Biotechnology | Director/Board Member | |
KINNATE BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
MOMA Therapeutics, Inc.
MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
Alpha-9 Oncology, Inc.
Alpha-9 Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Biotechnology | Director/Board Member | |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
8stogg AG | Director/Board Member | ||
Alterome Therapeutics, Inc.
Alterome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alterome Therapeutics, Inc. is a precision oncology biotech that develops alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is based in San Marcos, CA. The company is led by seasoned R&D leaders with a history of developing marketed oncology small molecule drugs. The company's mission is to discover precise therapies and inspire hope for individuals affected by cancer. The CEO of the company is Eric A. Murphy. | Pharmaceuticals: Major | Director/Board Member | |
Wemedoo AG | Chairman | ||
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
Stati Uniti | 32 |
Svizzera | 7 |
Irlanda | 6 |
Regno Unito | 4 |
Germania | 3 |
Settori
Health Technology | 28 |
Consumer Services | 8 |
Miscellaneous | 7 |
Commercial Services | 6 |
Finance | 4 |
Posizioni
Director/Board Member | 61 |
Independent Dir/Board Member | 11 |
Corporate Officer/Principal | 8 |
Private Equity Investor | 7 |
Private Equity Analyst | 6 |
Contatti più connessi
- Borsa valori
- Insiders
- Lukas Rindlisbacher
- Connessioni Società